1Wilkins HJ, Crane MM, Copeland K, et al. Hypereosinophilic syndrome: An Update. Am J Hematol,2005,80(2): 148- 157.
2Fruebauf S, Fiehn C, Haas R, et al. Sustained remission of idiopathichyereosinophilic syndrome following a2 interferon therapy [J ]. Acta Haematol, 1993,89(2) :91 - 93.
3Muller AM, MartensUM, Hofmann SC, et al. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: twocase reports and a comprehensive review of the literature. Ann Hematol, 2006, 85 (1):12- 16.
2Fauci AS, Harley JB, Robert WC, et al. The idiopathic hyperersinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations. Ann intern Med 1982; 97:78-92
3Rothenberg ME. Eosinophilia. N Engl J Med 1998, 338: 1592-1600
4Roche S. Cross S. Kaufman B. Intracranial hemorrhages occurring in the idiopathic hypereosinophilic syndrome. J Neurol Neurosurg Psychiatry 1990; 53:440-441
5Spry Cl. The hypereosinophilic syndrome: Clinical features, laboratory finding and treatment. Allergy 1982; 37:539-547
6Kaplan PW, Waterbury L, Kawas C. et al. Reversible dementia with idiopathic hypererosinophilic syndrome. Neurology 1989; 39:1388-1390
7Weaver DF, Helferman LP, Purdy RA, et al. Eosinophili-induced neurotoxicity: Axonal neuropathy, cerebral infarction and dementia. Neurology 1988; 38:144-148
8Cools J, DeAngelo DJ, Gotlib J, et al. A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome N Eng J Med 2003; 348:1201～1214
9Mooke PM, Harley JB,Fauci AS, et al. Neurologic dysfunction in idiopathic hypereosinophilic syndrome. Ann Intern Med 1985,102:109-114
10Filley CM, Kleinschmidt-DeMasters. Toxic leukoencephalopathy. N Eng J Meal 2001; 346:425-432
